Epigenetics in cancer: Targeting chromatin modifications

被引:349
作者
Ellis, Leigh [1 ]
Atadja, Peter W. [2 ]
Johnstone, Ricky W. [1 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia
[2] Novartis Inst Biomed Res, Cambridge, MA USA
基金
英国医学研究理事会;
关键词
HISTONE-DEACETYLASE INHIBITORS; SMALL-MOLECULE INHIBITOR; ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENES; IN-VIVO ACTIVITY; DNA METHYLATION; CLASS-II; DEMETHYLATING AGENTS; CLINICAL DEVELOPMENT; THERAPEUTIC TARGETS;
D O I
10.1158/1535-7163.MCT-08-0860
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Posttranslational modifications to histones affect chromatin structure and function resulting in altered gene expression and changes in cell behavior. Aberrant gene expression and altered epigenomic patterns are major features of cancer. Epigenetic changes including histone acetylation, histone methylation, and DNA methylation are now thought to play important roles in the onset and progression of cancer in numerous tumor types. Indeed dysregulated epigenetic modifications, especially in early neoplastic development, may be just as significant as genetic mutations in driving cancer development and growth. The reversal of aberrant epigenetic changes has therefore emerged as a potential strategy for the treatment of cancer. A number of compounds targeting enzymes that regulate histone acetylation, histone methylation, and DNA methylation have been developed as epigenetic therapies, with some demonstrating efficacy in hematological malignancies and solid tumors. This review highlights the roles of epigenetic modifications to histones and DNA in tumorigenesis and emerging epigenetic therapies being developed for the treatment of cancer. [Mol Cancer Ther 2009;8(6):1409-20]
引用
收藏
页码:1409 / 1420
页数:12
相关论文
共 120 条
[71]   Mechanisms involved in the regulation of histone lysine demethylases [J].
Lan, Fei ;
Nottke, Amanda Clair ;
Shi, Yang .
CURRENT OPINION IN CELL BIOLOGY, 2008, 20 (03) :316-325
[72]   Acute mixed lineage, leukemia with an inv(8)(p11g13) resulting in fusion of the genes for MOZ and TIF2 [J].
Liang, J ;
Prouty, L ;
Williams, BJ ;
Dayton, MA ;
Blanchard, KL .
BLOOD, 1998, 92 (06) :2118-2122
[73]   Transcriptional regulation in acute promyelocytic leukemia [J].
Lin, RJ ;
Sternsdorf, T ;
Tini, M ;
Evans, RM .
ONCOGENE, 2001, 20 (49) :7204-7215
[74]   Crystal structure of the nucleosome core particle at 2.8 angstrom resolution [J].
Luger, K ;
Mader, AW ;
Richmond, RK ;
Sargent, DF ;
Richmond, TJ .
NATURE, 1997, 389 (6648) :251-260
[75]   HDACs and HDAC inhibitors in colon cancer [J].
Mariadason, John M. .
EPIGENETICS, 2008, 3 (01) :28-37
[76]   Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state [J].
McGarvey, KM ;
Fahrner, JA ;
Greene, E ;
Martens, J ;
Jenuwein, T ;
Baylin, SB .
CANCER RESEARCH, 2006, 66 (07) :3541-3549
[77]   Sirtuins in mammals: insights into their biological function [J].
Michan, Shaday ;
Sinclair, David .
BIOCHEMICAL JOURNAL, 2007, 404 :1-13
[78]   The Sirtuin family: therapeutic targets to treat diseases of aging [J].
Milne, Jill C. ;
Denu, John M. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2008, 12 (01) :11-17
[79]   Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer [J].
Miranda, E. ;
Destro, A. ;
Malesci, A. ;
Balladore, E. ;
Bianchi, P. ;
Baryshnikova, E. ;
Franchi, G. ;
Morenghi, E. ;
Laghi, L. ;
Gennari, L. ;
Roncalli, M. .
BRITISH JOURNAL OF CANCER, 2006, 95 (08) :1101-1107
[80]   Cancer genetics of epigenetic genes [J].
Miremadi, Ahmad ;
Oestergaard, Mikkel Z. ;
Pharoah, Paul D. P. ;
Caldas, Carlos .
HUMAN MOLECULAR GENETICS, 2007, 16 :R28-R49